Sham-Controlled Prospective Study Characterizing Erectile Tissue Ultrasound Changes Resulting From Penile LiSWT

This is a single site sham-controlled clinical trial to be conducted at San Diego Sexual Medicine in San Diego, California. Subjects meeting inclusion and exclusion criteria will be randomized to one of two arms, each 2:1 active to sham, treated in 3-week cycles. Arm 1 consists of 5000 shocks the first week and two weeks off for each of three treatment cycles. Arm 2 is made up of 5000 shocks the first week and 3000 active shocks the second and third weeks followed by three weeks without treatment, and then 5000, 3000 and 3000 shocks again over the next three weeks. Each of these is followed by the first follow-up visit at 20 weeks after the first treatment, when GUS and DUS is repeated and validated instruments completed, at which time treatment will be unblinded. SEP diaries will be completed during sexual activity in the screening period and during the 4 weeks prior to the follow up visit. Those subjects assigned to sham will be crossed over to the opposite arm for active treatment (arm 1 sham goes to arm 2 open label and arm 2 sham to arm 1 open label) and begin active treatment with decreased intervals between shocks and therefore decreased number of shocks needed, with 3500 rather than 5000 shocks and 2000 rather than 3000 shocks at a lower frequency at that visit after completing the follow up procedures. Subjects assigned initially to the active arm will have a second follow up 32 weeks after the first treatment, and complete SEP diaries during the 4 weeks preceding this visit. GUS and DUS is performed and validated instruments completed at the last follow up.

Inclusion criteria

• Subject provides written informed consent and HIPAA authorization before any study procedures are conducted;
• Subject is male;
• Subject is aged 21-80 years;
• Subject is in a relationship with a female partner for at least 3 months;
• Subject has a body mass index (BMI) < 37 kg/m2;
• Subject has erectile dysfunction;
• Subject has testosterone ≥ 300;
• Subject has a prostate specific antigen (PSA) < 4.0;
• Subject is willing to attempt sexual activity at least 4 times during the screening period and 4 weeks before each follow-up visit;
• Subject is willing to stop all erectile function aids (e.g. prescription and non-prescription medications, injections, vacuum erection devices, constriction ring) during the screening period and 4 weeks before each follow-up visit;
• Subject agrees to comply with the study procedures and visits.

Exclusion criteria

• Subject has been treated with acoustic wave previously;
• Subject has a pacemaker or implanted defibrillator;
• Subject has clinically significant findings on physical examination;
• Subject has sciatica or severe back pain;
• Subject has uncontrolled hypertension;
• Subject has uncontrolled hypogonadism;
• Subject is unwilling to maintain testosterone replacement therapy if currently using testosterone to treat hypogonadism;
• Subject scores ≥ 26 on the IIEF;
• Subject has homogenous corpora cavernosa on grey scale ultrasound;
• Subject has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes him ineligible for the study;
• Subject has lesions or active infections on the penis or perineum;
• Subject is unwilling to remove piercings from the genital region;
• Subject has a history of substance abuse within 12 months prior, or consuming > 14 alcoholic drinks per week;
• Subject has received an investigational drug within 30 days prior to signing consent;
• Subject has received platelet rich plasma (PRP) within 3 months of signing consent;
• Subject has received stem cell within 6 months of signing consent;
• Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.